Follistatin (FLGR242)

Follistatin (FLGR242) is a recombinant isoform of the naturally occurring follistatin glycoprotein, engineered to preserve full binding activity against its primary research targets: myostatin and activin. Follistatin is a secreted glycoprotein that functions as a potent endogenous inhibitor of TGF-β superfamily members — a family of signaling proteins that includes myostatin (GDF-8), activin A, activin B, BMP-2, and BMP-4. By binding and neutralizing these molecules, follistatin acts as a master regulator of muscle mass, metabolic function, reproductive biology, and tissue homeostasis.

The FLGR242 designation refers to a truncated recombinant form that retains the key follistatin domains responsible for ligand binding while offering improved solubility and stability compared to full-length preparations. This makes it a versatile tool for research applications requiring consistent and reproducible bioactivity. Manufactured under GMP-compliant conditions with independent third-party purity verification, research-grade FLGR242 is designed to meet the quality standards demanded by rigorous scientific investigation.

Follistatin (FLGR242) – Benefits & Side Effects

Benefits: Follistatin's most extensively studied function in research models is the promotion of skeletal muscle hypertrophy through myostatin inhibition. Myostatin (GDF-8) is the primary endogenous brake on muscle growth — it limits satellite cell activation, protein synthesis, and muscle fiber size. In animal models, follistatin overexpression or administration consistently produces dramatic increases in muscle mass, ranging from 200–300% in some transgenic studies, demonstrating the magnitude of myostatin's restraining influence on muscle development.

Beyond muscle biology, follistatin's inhibition of activin signaling has implications for reproductive research (activin regulates FSH secretion), metabolic research (activin A influences adipogenesis and glucose metabolism), and inflammation research (activin A is a pro-inflammatory cytokine upregulated in chronic inflammatory states). Research has also explored follistatin's role in bone biology, where its inhibition of BMP antagonism may have relevance to bone density and repair research.

Emerging research has highlighted follistatin's potential relevance to aging biology. Myostatin and activin signaling are elevated in aged muscle tissue, contributing to the progressive loss of muscle mass (sarcopenia) that characterizes biological aging. Interventions that restore more youthful myostatin/activin signaling ratios are of significant research interest in the context of longevity and healthspan science.

Side Effects: In animal models, excessive follistatin activity has been associated with reproductive effects (suppression of FSH-driven folliculogenesis), over-proliferation of certain tissue types, and effects on bone density at high doses. Research doses designed to replicate physiological inhibition profiles have shown a more favorable safety window. Thorough dose-response characterization is a standard requirement in preclinical follistatin research.

Follistatin (FLGR242) – Mechanism of Action

Follistatin functions as a high-affinity binding protein for TGF-β superfamily ligands. The protein contains three follistatin domain repeats (FSD1, FSD2, FSD3) and an N-terminal domain, each contributing to ligand binding. The heparin-binding region of follistatin is responsible for anchoring the protein to cell surfaces and the extracellular matrix, creating local reservoirs of inhibitory activity that modulate signaling in a spatially controlled manner.

Upon binding to myostatin or activin, follistatin prevents these ligands from engaging their cognate receptors (ActRIIA and ActRIIB), blocking downstream Smad2/3 phosphorylation and the transcriptional programs that limit muscle protein synthesis and promote muscle atrophy. This is mechanistically distinct from approaches that target the receptors directly (such as ActRIIB antibodies), offering a complementary research tool for dissecting TGF-β superfamily biology.

The FLGR242 variant retains FSD1 and FSD2 with high structural fidelity to the native sequence, providing robust myostatin and activin binding. Its truncated C-terminus reduces heparin-binding affinity relative to full-length follistatin-344, altering its tissue distribution profile and making it particularly useful for systemic in vitro studies where localization effects must be controlled.

Follistatin (FLGR242) vs Follistatin-344 & 315

Researchers working with follistatin preparations will encounter three primary forms: follistatin-344, follistatin-315, and FLGR242. Follistatin-344 is the primary circulating isoform, with high heparin-binding affinity that results in tissue sequestration — it acts predominantly in the local tissue environment. Follistatin-315 lacks the heparin-binding C-terminal extension, giving it a longer systemic half-life and greater suitability for studies examining circulatory effects. FLGR242 represents a recombinant truncated form with optimized manufacturing characteristics and defined binding properties, making it particularly well-suited for standardized cell culture and biochemical research applications.

Follistatin (FLGR242) – Research Highlights

A landmark 2009 study by Lee et al. demonstrated that intramuscular injection of follistatin gene constructs in non-human primates produced significant and sustained muscle mass increases without detectable adverse effects after 15 months of observation. This study was foundational in establishing follistatin as a serious candidate for research into muscle-wasting diseases including muscular dystrophy, cachexia, and sarcopenia.

Clinical translation efforts have been documented in a small human study published in Science Translational Medicine (Mendell et al., 2015), where intramuscular follistatin gene delivery in Becker muscular dystrophy patients produced measurable improvements in the 6-minute walk test and favorable muscle pathology histology, establishing proof-of-concept for therapeutic follistatin delivery in humans.

Research using follistatin-based interventions in metabolic models has demonstrated effects on adipose tissue differentiation and glucose metabolism, with activin A inhibition linked to improved insulin sensitivity in diet-induced obesity models. These findings have expanded the research scope of follistatin beyond muscle biology into the broader field of metabolic disease.

Follistatin (FLGR242) – Protocol

Follistatin FLGR242 (10mg)

Goal: Support investigation of myostatin inhibition, muscle tissue biology, activin signaling pathways, and related TGF-β superfamily research applications.

Preparation: Reconstitute with sterile bacteriostatic water or PBS to a stock concentration of 1 mg/mL. Gently swirl to dissolve — do not vortex. Allow 10 minutes at room temperature. Follistatin is a glycoprotein and can be sensitive to mechanical disruption.

Working concentrations (in vitro): For myostatin inhibition assays, concentrations of 100–500 ng/mL are commonly used to achieve full pathway suppression. For dose-response experiments, a range of 10–1000 ng/mL is recommended to characterize the EC50 for the specific endpoint.

Dosing in animal models: Published animal studies have used dosing ranges of 1–10 µg per administration via intramuscular or subcutaneous routes, with frequency determined by the experimental design. Tissue-specific effects may vary depending on route of administration and the follistatin isoform used.

Proper Peptide Storage

Store lyophilized Follistatin (FLGR242) at −20°C or −80°C, protected from moisture and light. Stable for 24 months under recommended conditions. Once reconstituted, aliquot into single-use volumes and store at −80°C for up to 3 months. Avoid freeze-thaw cycles. Working solutions prepared at 4°C should be used within 48 hours.

Follistatin (FLGR242) – Identification

Chemical Name: Recombinant Human Follistatin (FLGR242, truncated isoform)
Molecular Weight: ~31.5 kDa (protein backbone); ~35–40 kDa (glycosylated)
Purity: ≥99% by HPLC and SDS-PAGE
Endotoxin: <1.0 EU/µg
Form: Lyophilized white powder
Activity: Confirmed myostatin binding by ELISA; biological activity validated in C2C12 myoblast differentiation assays

Follistatin (FLGR242) – Research Links

• Lee SJ et al. (2009). Regulation of muscle growth by multiple ligands signaling through ActRIIB. PNAS, 102(50), 18117–18122.
• Mendell JR et al. (2015). Follistatin gene therapy for Becker muscular dystrophy. Science Translational Medicine, 7(287), 287ra74.
• Rodino-Klapac LR et al. (2009). Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle & Nerve, 39(3), 283–296.
• Breit SN et al. (2011). The TGF-β superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors, 29(5), 187–195.